Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€820.00

€820.00

0.610%
5.0
0.610%
€831.01

€831.01

 
08:00 / Tradegate WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€795.53
16.09.24
-1.22%
buy
15.09.24
-2.15%
buy
€920.00
14.09.24
-2.15%
buy
14.09.24
-2.15%
buy
€992.31
13.09.24
-2.75%
buy
€954.74
13.09.24
-3.23%
buy
Best running prediction
€599.82
02.10.23
63.62%
buy
Your prediction

Eli Lilly Corp. Stock

Eli Lilly Corp. gained 0.610% compared to yesterday.
The stock is an absolute favorite of our community with 75 Buy predictions and no Sell predictions.
With a target price of 831 € there is a slightly positive potential of 1.34% for Eli Lilly Corp. compared to the current price of 820.0 €.
Our community identified positive and negative aspects for Eli Lilly Corp. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Eli Lilly Corp. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.

Pros and Cons of Eli Lilly Corp. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Eli Lilly Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Eli Lilly Corp. 0.610% -2.419% -2.535% 52.479% 54.356% 315.498% 697.768%
Johnson & Johnson -0.010% 0.013% 3.457% -1.566% 5.664% 6.552% 26.561%
Elanco Animal Health Inc. -1.330% -0.850% -1.597% 18.297% -3.402% -52.733% -
Biogen Inc. 0.340% -1.550% -2.867% -24.958% -24.576% -30.487% -16.561%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Eli Lilly (NYSE: LLY) indicate a robust position within the pharmaceutical industry. With a strong market capitalization of approximately $678 billion, the company exhibits significant revenue and profitability levels, which suggests a well-managed operation with a focus on research and development. However, several key ratios also hint at potential challenges that investors should consider.

When analyzing Eli Lilly's financials in detail, both strengths and weaknesses emerge, providing an overarching view of the company's financial health.

Strong Revenue Performance: Eli Lilly reported a total revenue of approximately $35.93 billion for the trailing twelve months (TTM), showcasing its capability to generate substantial income. This impressive revenue figure is supported by a healthy gross profit of about $21.91 billion, translating to a gross margin of around 61.7%.

Comments

Prediction Buy
Perf. (%) -1.22%
Target price 795.527
Change
Ends at 16.09.25

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.
Ratings data for LLY provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.15%
Target price 920.000
Change
Ends at 14.09.25

Man, Eli Lilly is on fire lately! They just got FDA approval for EBGLYSS, their new eczema treatment, which could be a game-changer. And they're pouring billions into expanding manufacturing - talk about confidence in their pipeline! With their obesity and diabetes drugs crushing it, and more promising candidates in the works, Lilly seems to be firing on all cylinders. The stock's had a great run already, but I think there's still room to grow. It ain't cheap, but quality rarely is. I'd say Lilly's worth a look for anyone wanting exposure to a top-tier pharma innovator.
Show more

Prediction Buy
Perf. (%) -2.75%
Target price 992.310
Change
Ends at 13.09.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,100.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Show more